Development of treatments for apicomplexa poultry pathogens****

在传染病中，球虫病和坏死性肠炎是家禽发病和死亡的两个主要原因。在世界范围内，每种疾病每年造成超过50亿美元的家禽生产损失。加拿大的损失估计是美国的10%，为6000万美元。家禽球虫病是由来自艾美耳球虫属的寄生虫引起的，最常见的是柔嫩艾美耳球虫，而巨型艾美耳球虫是家禽坏死性肠炎发展的最常见诱发因素。虽然这两种疾病都有疫苗，但目前还不能充分控制这种疾病。NovoBind畜牧治疗公司提出开发新的基于抗体的策略，其可以掺入家禽饲料中以预防球虫病和坏死性肠炎的发展。** 柔嫩艾美耳球虫和巨型艾美耳球虫是被称为顶复门寄生虫的较大寄生虫群的一部分。该提案依赖于Martin Boulanger博士及其实验室在apicomplexan疾病关键决定因素方面的专业知识。本文所述的工作将使NovoBind能够产生针对该关键决定簇的抗体，并将支持NovoBind已经产生的新型柔嫩艾美耳球虫特异性和巨型艾美耳球虫特异性抗体（NBXs）。针对球虫病和坏死性肠炎的预防性产品的开发将使加拿大和世界各地的家禽生产者受益。NovoBind在提供这一产品方面所产生的收入也将对加拿大的经济产生推动作用。此外，如果成功，这项工作将为开发类似的治疗方法奠定基础，用于治疗由顶复门寄生虫引起的人类疾病，包括疟疾和弓形虫病。

Amongst infectious diseases, coccidiosis and necrotic enteritis are two of the leading causes of morbidity and mortality in poultry. Worldwide, each disease causes greater than $5 billion dollars in poultry production losses annually. Canadian losses are estimated to be 10% of the US at 60 million USD. Poultry coccidiosis is cause by parasites from the genus Eimeria, most commonly Eimeria tenella, while Eimeria maxima is the most common predisposing factor for the development of poultry necrotic enteritis. Although vaccines exist for both conditions, they currently fail to adequately control the disease. NovoBind Livestock Therapeutics Inc. proposes to develop novel antibody-based strategies that could be incorporated into poultry feed to prevent the development of coccidiosis and necrotic enteritis. **Eimeria tenella and Eimeria maxima are part of a larger group of parasites known as apicomplexan parasites. This proposal relies on the expertise of Dr. Martin Boulanger and his laboratory in the key determinants of apicomplexan diseases. The work described here will enable NovoBind to generate antibodies targeting this key determinant and will bolster the novel Eimeria tenella-specific and Eimeria maxima-specific antibodies (NBXs) NovoBind has already generated. The development of prophylactic products targeting coccidiosis and necrotic enteritis would benefit poultry producers in Canada and around the world. The revenue generated by NovoBind in delivering this product would also be an economic boost to Canada. Furthermore, if successful this work will set the stage to develop similar therapeutics for human diseases caused by apicomplexan parasites, which include malaria and toxoplasmosis.**